Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Welchol Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients

By Pharmaceutical Processing | October 7, 2009

Daiichi Sankyo, Inc. (DSI)announced today that the FDA has approvedthe supplemental new drug application (sNDA) for Welchol (colesevelam HCl) tobe used as an adjunct to diet and exercise for the reduction of elevatedlow-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls,10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH)alone or in combination with a statin after failing an adequate trial of diettherapy. Originally approved in 2000 for LDL-C lowering and in 2008 for A1Creduction in adults, Welchol is approved as an adjunct to diet and exercise toreduce elevated LDL-C in adults with primary hyperlipidemia and improveglycemic control in adults with type 2 diabetes mellitus. Familial hypercholesterolemia (FH) is a genetic disorder resulting inelevated LDL cholesterol and increased risk of cardiovascular disease(CVD).(1) There are 10 million people with FH worldwide, the majority of whomhave heFH.(2) “The FDA approval of Welchol for children with inherited high cholesterolprovides another important treatment option for these children, whose elevatedLDL cholesterol puts them at increased risk for cardiovascular disease…,” saidEvan A. Stein, MD, PhD, Director, Metabolic & Atherosclerosis Research Center,Cincinnati, OH. “The pivotal trial of Welchol in this pediatric patientpopulation demonstrated that Welchol, as monotherapy or when combined with astatin, significantly reduced LDL-C.”

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards